Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

TB Notes Newsletter

(PDF - 1 MB)

No. 2, 2014

NEW CDC PUBLICATIONS

Baker BJ, Jeffries CD, Moonan PK. Decline in Tuberculosis among Mexico-Born Persons in the United States, 2000-2010. Ann Am Thorac Soc 2014 Apr 7. [Epub ahead of print.]

Bansal AK, Kulshrestha N, Nagaraja SB, Rade K, Choudhary A, Parmar M, Nair SA, Dewan PK, Yadav R, Moonan PK. Composite indicator: new tool for monitoring RNTCP performance in India. Int J Tuberc Lung Dis 2014 Jul;18(7):840-2. http://www.ncbi.nlm.nih.gov/pubmed/24902562

Berzkalns A, Bates J, Ye W, Mukasa L, France AM, et al. The road to tuberculosis (Mycobacterium tuberculosis) elimination in Arkansas; a re-examination of risk groups. PLoS ONE 2014; 9(3): e90664. doi:10.1371/journal.pone.0090664.

Bharaswadkar S, Kanchar A, Thakur N, Shah S, Patnaik B, Click ES, Kumar AM, Dewan PK. Tuberculosis Management Practices of Private Practitioners in Pune Municipal Corporation, India. PLoS ONE 2014; 9(6): e97993. doi:10.1371/journal.pone.0097993.

Blaya JA, Shin SS, Yagui M, Contreras C, Cegielski P, Yale G, Suarez C, Asencios L, Bayona J, Kim J, Fraser HS. Reducing communication delays and improving quality of care with a tuberculosis laboratory information system in resource poor environments: a cluster randomized controlled trial. PLoS One 2014 Apr 10;9(4):e90110. doi: 10.1371/journal.pone.0090110.

Chuke SO, Yen NT, Laserson KF, Phuoc NH, Trinh NA, Nhung DT, Mai VT, Qui AD, Hai HH, Loan le TH, Jones WG, Whitworth WC, Shah JJ, Painter JA, Mazurek GH, Maloney SA. Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants. Tuberc Res Treat. 2014;2014:217969. doi: 10.1155/2014/217969. Epub 2014 Mar 6.

Coleman MS, Marienau KJ, Marano N, Marks SM, Cetron MS. Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis. Travel Med Infect Dis 2014 Jan-Feb;12(1):63-71.

De Beer JL, Kodmon C, Van Ingen J, Jamieson FB, Bidovec-Stojkovic U, Brown T, Cirillo DM, Cruz L, Miranda A, Dou HY, Fauville-Dufaux M, Fitzgibbon MM, Garcia De Viedma D, Groenheit R, Haanpera-Heikkinen M, Indra A, Kam KM, Kramer R, Jiang GL, Niemann S, Obrovac M, Rasmussen EM, Refregier G, Realpe T, Samper S, Sharma MK, Sougakoff W, Stakenas P, Stavrum R, Trenkler J, Wada T, Siame KK, Tafaj S, Cowan L, Sng LH, Seagar AL, Basu I, Rastogi N, Ferro BE, De Matos F, Kipnis A, Van Soolingen D, Supply P. Second worldwide proficiency study on variable number of tandem repeats typing of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis. 2014 01 May;18(5):594-600+i.

Egelund EF, Weiner M, Singh RP, Prihoda TJ, Gelfond JA, Derendorf H, Mac Kenzie WR, Peloquin CA. Protein Binding of Rifapentine and the 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2014 May 19. pii: AAC.01730-13. [Epub ahead of print]

Elmore K, Nelson R, Gant Z, Jeffries C, Broeker L, Mirabito M, Roberts H. Data harmonization process for creating the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Atlas. Public Health Rep 2014 Jan-Feb;129 Suppl 1:63-9.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP, et al. Mortality among tuberculosis patients with acquired resistance to second-line anti-tuberculosis drugs - United States, 1993-2008. Clin Infect Dis 2014.

Ershova JV, Podewils LJ, Bronner E, Stockwell HG, Dlamini S, Mametja LD. Evaluation of adherence to national treatment guidelines among tuberculosis patients in three provinces of South Africa. S Afr Med J. 2014 ;104(5):362-368.

Fiske CT, Yan F-X, Hirsch-Moverman Y, Sterling TR, Reichler MR, for the Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. The International Journal of Tuberculosis and Lung Disease 2014 Apr 1; 18 (4): 421-427.

Goodwin DJ, Mazurek GH, Campbell BH, Bohanon J, West KB, Bell JJ, Powell R, Toney S, Morris JA, Yamane GK, Sjoberg PA. Automation of an Interferon-γ release assay and comparison to the tuberculin skin test for screening basic military trainees for Mycobacterium tuberculosis infection. Military Medicine 2014 March; 179 (3): 333-341. doi: http://dx.doi.org/10.7205/MILMED-D-13-00364.

Graham SM, Sismanidis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance of tuberculosis control to address child survival. Lancet 2014 Mar 21. pii: S0140-6736(14) 60420-7. doi: 10.1016/S0140-6736(14)60420-7. [Epub ahead of print.]

Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV. How we determined the most reliable solid medium for studying treatment of tuberculosis. Tuberculosis (Edinb) 2014 May. doi: 10.1016/j.tube.2014.02.006.

Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD. What is the most reliable solid culture medium for tuberculosis treatment trials? Tuberculosis (Edinb). 2014 May. pii: S1472-9792(14)00029-8. doi: 10.1016/j.tube.2014.03.002.

Kong D, Watt JP, Marks SM, Flood JM. Timely HIV Diagnosis and HIV/TB Comanagement Among California Patients in 2008. Public Health Rep 2014 Mar; 129(2):170-7.

Lam E, Nateniyom S, Whitehead S, Anuwatnonthakate A, Monkongdee P, Kanphukiew A, Inyaphong J, Sitti W, Chiengsorn N, Moolphate S, Kavinum S, Suriyon N, Limsomboon P, Danyutapolchai J, Sinthuwattanawibool C, Podewils LJ. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008. Emerg Infect Dis 2014 Mar;20(3):408-16.

Marienau KJ, Cramer EH, Coleman MS, Marano N, Cetron MS. Flight related tuberculosis contact investigations in the United States: Comparative risk and economic analysis of alternate protocols. Travel Med Infect Dis 2014 Jan-Feb;12(1):54-62. doi: 10.1016/j.tmaid.2013.09.007.

Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis [Internet]. 2014 May; http://dx.doi.org/10.3201/eid2005.131037. DOI: 10.3201/eid2005.131037

Medrano BA, Salinas G, Sanchez C, Miramontes R, Restrepo BI, Haddad MB, Lambert LA. A missed tuberculosis diagnosis resulting in hospital transmission. Infect Control Hosp Epidemiol. 2014 May;35(5):534-7.

Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb) 2014 Feb 7. pii: S1472-9792(14)00022-5. doi: 10.1016/j.tube.2014.01.006. [Epub ahead of print].

Oeltmann JE, Click ES, Moonan PK. Using tuberculosis patient characteristics to predict future cases with matching genotype results. Public Health Action 2014 March 1; 4 (1): 47-52.

Reilley B, Bloss E, Byrd KK, Iralu J, Neel L, and Cheek J. Death rates from human immunodeficiency virus and tuberculosis among American Indians/Alaska Natives in the United States, 1990–2009. American Journal of Public Health 2014; e-View ahead of print April 22, 2014; e1–e7. doi:10.2105/AJPH.2013.301746.

Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Dukes Hamilton C, Bock N, Narita M, D. Wing, Hershfield E, Goldberg SV, for the Tuberculosis Trials Consortium. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. IJTLD 2014 May 1; 18 (5): 571-580.

Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-3042. Epub 2014 Mar 10.

Weiner M, Savic RM, Mac Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JAL, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME, for the Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Ped Infect Dis2014 3: 132-145.

Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM. Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol 2014; doi:10.1128/JCM.00417-14.

Reported by Ann Lanner
Div of TB Elimination

Top of Page

 
Contact Us:
  • Centers for Disease Control and Prevention
    Division of Tuberculosis Elimination (DTBE)
    1600 Clifton Rd., NE
    MS E10
    Atlanta, GA 30329
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
  • Page last reviewed: April 21, 2014
  • Page last updated: April 21, 2014
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO